BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1637 related articles for article (PubMed ID: 27507876)

  • 1. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in
    Noronha V; Patil VM; Joshi A; Menon N; Chougule A; Mahajan A; Janu A; Purandare N; Kumar R; More S; Goud S; Kadam N; Daware N; Bhattacharjee A; Shah S; Yadav A; Trivedi V; Behel V; Dutt A; Banavali SD; Prabhash K
    J Clin Oncol; 2020 Jan; 38(2):124-136. PubMed ID: 31411950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
    Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
    Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
    J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    Yang JC; Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Hozak RR; Nguyen TS; Zhang WL; Enatsu S; Puri T; Orlando M
    J Thorac Oncol; 2020 Jan; 15(1):91-100. PubMed ID: 31605797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
    Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
    Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
    Mok TSK; Kim SW; Wu YL; Nakagawa K; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress KS; Soria JC
    J Clin Oncol; 2017 Dec; 35(36):4027-4034. PubMed ID: 28968167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
    Boye M; Wang X; Srimuninnimit V; Kang JH; Tsai CM; Orlando M; Puri T; Kim JS; Rajan N; Yang JC
    Clin Lung Cancer; 2016 Mar; 17(2):150-60. PubMed ID: 26809984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
    Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
    Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
    Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study.
    Yang JC; Srimuninnimit V; Ahn MJ; Lin CC; Kim SW; Tsai CM; Mok T; Orlando M; Puri T; Wang X; Park K
    J Thorac Oncol; 2016 Mar; 11(3):370-9. PubMed ID: 26725183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
    Ahn MJ; Yang JC; Liang J; Kang JH; Xiu Q; Chen YM; Blair JM; Peng G; Linn C; Orlando M
    Lung Cancer; 2012 Aug; 77(2):346-52. PubMed ID: 22534669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.